+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Immunogenicity of Renal Microvascular Endothelial Cells From Genetically Modified Pigs

Immunogenicity of Renal Microvascular Endothelial Cells From Genetically Modified Pigs

Transplantation 100(3): 533-537

Disrupting the porcine GGTA1 and CMAH genes [double knockout (DKO)] that produce the gal-α(1,3)-gal and N-glycolylneuraminic acid xenoantigens reduces human antibody binding to porcine peripheral blood mononuclear cells. It is important to examine rejection pathways at an organ-specific level. The object of this study is to evaluate the human preformed antibody reactivity against DKO renal microvascular endothelial cells (RMEC) in vitro. Characteristics of DKO RMEC were analyzed using flow cytometry. Human IgG/M binding to primary RMEC, immortalized RMEC (iRMEC), and iRMEC-deficient in B4GALNT2 genes were examined using flow cytometric crossmatch assay. Porcine RMEC expressed gal-α(1,3)-gal, N-glycolylneuraminic acid, and Dolichos biflorus agglutinin glycans recognized by human preexisting antibodies in humans. Antigenicity of DKO RMEC was lower than GGTA1 KO RMEC. The disruption of B4GALNT2 gene in DKO iRMEC further reduced human IgG/IgM binding. Silencing the porcine GGTA1, CMAH, and B4GALNT2 genes is an effective strategy to reduce human preformed antibody binding to RMEC. Porcine RMEC will be a useful reagent for the further study of xenoimmunology.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058051803

Download citation: RISBibTeXText

PMID: 26906938

DOI: 10.1097/tp.0000000000001070

Related references

Adipose-derived mesenchymal stromal cells from genetically modified pigs: immunogenicity and immune modulatory properties. CytoTherapy 14(4): 494-504, 2012

Systemic delivery of human growth hormone using genetically modified tissue-engineered microvascular networks: prolonged delivery and endothelial survival with inclusion of nonendothelial cells. Tissue Engineering 8(6): 1057-1069, 2002

In vivo expression of hgh from genetically augmented human microvascular endothelial cells in three dimensional matrigel. Journal of Cellular Biochemistry Suppl. (16 Part F): 128, 1992

Potentiation of immunogenicity and modulation of lymphokine profile in house dust mite specific T cells by genetically modified allergen. Journal of Allergy & Clinical Immunology 105(1 part 2): S327, 2000

Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma. British Journal of Urology 79(5): 681-687, 1997

Novel anticancer vaccine using genetically modified endothelial cells. European Urology Suppl.s 2(1): 44, 2003

Repopulation of injured arteries with genetically modified endothelial cells. Journal of Vascular Surgery 15(5): 932-934, 1992

Attachment, replication and thrombogenicity of genetically modified endothelial cells. European Journal of Vascular and Endovascular Surgery 9(3): 335-340, 1995

Transplantation of genetically modified human corneal endothelial cells. Investigative Ophthalmology & Visual Science 35(4): 1384, 1994

Genetically modified endothelial cells in the treatment of human diseases. Transactions of the Association of American Physicians 102: 139-147, 1989

Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells. Clinical Cancer Research 6(11): 4442-4448, 2000

Implantation of vascular grafts lined with genetically modified endothelial cells. Science 244(4910): 1344-1346, 1989

Angiogenesis-directed implantation of genetically modified endothelial cells in mice. Cancer Research 55(11): 2240-2244, 1995

Seeding of intravascular stents by the xenotransplantation of genetically modified endothelial cells. Seminars in Interventional Cardiology 3(3-4): 217-220, 1999